Yes, Add Prednisone for COPD Exacerbation
Even in a patient already on maintenance prednisone with a solitary kidney, you should increase the prednisone dose to treat the acute COPD exacerbation. The standard recommendation is 30-40 mg prednisone daily for 5 days 1, which shortens recovery time, improves lung function, and reduces treatment failure risk.
Dosing Strategy
The FDA label explicitly addresses this scenario: "changes in clinical status secondary to remissions or exacerbations in the disease process...may make it necessary to increase the dosage of PredniSONE for a period of time consistent with the patient's condition" 2. This directly supports temporarily increasing the dose during an acute exacerbation, even when already on maintenance therapy.
Recommended Approach:
- Increase to 30-40 mg daily for 5 days (the evidence-based standard) 1
- This dose is effective regardless of baseline maintenance dose
- After 5 days, return to the previous maintenance dose
- No need to taper if treatment duration ≤14 days 1
Evidence Supporting Treatment
The 2017 ERS/ATS guideline recommends a short course (≤14 days) of oral corticosteroids for ambulatory COPD exacerbations 1. The GOLD strategy document specifically endorses 30-40 mg prednisone per day for 5 days 1. This recommendation prioritizes reducing treatment failure and improving recovery, accepting the uncertainty around adverse events.
Recent meta-analysis confirms that low-dose corticosteroids (≤40 mg prednisone equivalent/day) are sufficient and safer than higher doses, with similar efficacy in reducing treatment failure and improving FEV1 3. Higher doses only increase hyperglycemia risk without additional benefit.
Special Considerations for Your Patient
The Solitary Kidney Concern:
While corticosteroids can cause fluid retention and hypertension 2, the short 5-day course poses minimal renal risk. The FDA label notes "dietary salt restriction may be advisable" 2, which is prudent here. The greater risk is undertreating the exacerbation, which increases mortality and hospitalization risk.
Already on Maintenance Prednisone:
The patient's HPA axis is already suppressed from chronic use 2. This actually makes the temporary dose increase safer because:
- No risk of abrupt withdrawal (they continue steroids)
- The body is already adapted to exogenous corticosteroids
- Return to maintenance dose is straightforward—no taper needed for short courses
Critical Pitfalls to Avoid
Don't underdose out of fear of side effects. One study showed prednisone may not help primary care outpatients with mild exacerbations 4, but this doesn't apply to patients sick enough to warrant treatment. The guideline evidence strongly supports treatment for moderate-severe exacerbations 1.
Don't use higher doses thinking "more is better." Doses >40 mg increase hyperglycemia risk (49.5% vs 33% in one ICU study 5) without improving outcomes 3. Even in ventilated patients, high-dose steroids showed no mortality benefit but significantly more hyperglycemia 5.
Monitor glucose closely given the solitary kidney and increased infection risk with hyperglycemia. This is the main adverse effect you'll encounter 5, 6.
Monitoring During Treatment
- Check blood glucose if diabetic or at risk
- Monitor blood pressure (fluid retention concern with solitary kidney)
- Assess for clinical improvement by day 3-5
- If no response, consider alternative diagnoses (pneumonia, PE, heart failure)
The evidence is clear: treat the exacerbation with standard-dose prednisone despite the maintenance therapy and solitary kidney. The mortality and morbidity risk of undertreating the exacerbation far exceeds the minimal additional risk from a 5-day course.